Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT01339312 | Study of the Purified Vero Rabies Vaccine - Serum Free in Comparison With the Reference Purified Vero Rabies Vaccine | PHASE3 | COMPLETED | 816 | — | — | Apr 1, 2011 | Sep 1, 2012 | May 28, 2014 | 1 | China |
Rabies virus neutralizing antibody (RVNA) titer as determined by rapid fluorescent focus inhibition test (RFFIT)
| Arm | Type | Description |
|---|---|---|
| VRVg Vaccine Group 1 | EXPERIMENTAL | Participants aged 18 years or older will receive Purified Vero Rabies Vaccine Serum Free (VRVg) |
| VRVg Vaccine Group 2 | EXPERIMENTAL | Participants aged 10 to 17 years will receive Purified Vero Rabies Vaccine Serum Free (VRVg) |
| Verorab Vaccine Group 1 | ACTIVE_COMPARATOR | Participants aged 18 years or older will receive Verorab Vaccine |
| Verorab Vaccine Group 2 | ACTIVE_COMPARATOR | Participants aged 10 to 17 years will receive Verorab Vaccine |
| Name | Type | Description |
|---|---|---|
| Purified inactivated rabies vaccine, serum free | BIOLOGICAL | 0.5 mL, Intramuscular |
| Purified Vero Rabies Vaccine | BIOLOGICAL | 0.5 mL, Intramuscular |
Inclusion Criteria: Adults (≥ 18 years) * Aged ≥ 18 years on the day of inclusion * Informed consent form has been signed and dated * Able to attend all scheduled visits and to comply with all trial procedures * For a woman of childbearing potential, use of an effective method of contraception or ...